Clinical TrialJun 1, 2026, 08:03 AM
Ascentage Pharma Presents Alrizomadlin & Olverembatinib Data at ASCO 2026
AI Summary
Ascentage Pharma presented positive clinical data for two key assets, alrizomadlin and olverembatinib, at ASCO 2026. Alrizomadlin showed preliminary antitumor activity and a manageable safety profile in pediatric solid tumors, including a complete response in rhabdomyosarcoma and 23.5% ORR in combination. Updated data for olverembatinib as a second-line CML-CP therapy demonstrated deepening responses (91.3% CCyR, 60.9% MMR at cycle 24) and a manageable safety profile. Additionally, olverembatinib combined with blinatumomab showed encouraging activity in CML-LBP and Ph+ BCP-ALL, with 91% CR/CRi and high MRD negativity rates in international patients.
Key Highlights
- Alrizomadlin monotherapy achieved one complete response in pediatric rhabdomyosarcoma.
- Alrizomadlin in combination with lisaftoclax showed 23.5% objective response rate in pediatric solid tumors.
- Alrizomadlin was included in China's "SPARK Plan" for pediatric solid tumor development.
- Olverembatinib as second-line CML-CP therapy achieved a 91.3% complete cytogenetic response rate at cycle 24.
- Olverembatinib as second-line CML-CP therapy achieved a 60.9% major molecular response rate at cycle 24.
- Olverembatinib combined with blinatumomab achieved 91% complete response or complete response with incomplete hematologic recovery in CML-LBP/Ph+ BCP-ALL.
- Olverembatinib combination achieved 80% minimal residual disease negativity in CML-LBP/Ph+ BCP-ALL.
Price Impact
More from AAPG